Skip to main content
Scope Fluidics S.A. logo

Scope Fluidics S.A. — Investor Relations & Filings

Ticker · SCP ISIN · PLSCPFL00018 LEI · 259400EUNFX4E2BEHU15 WAR Professional, scientific and technical activities
Open in API
Filings indexed 510 across all filing types
Latest filing 2020-10-29 Capital/Financing Update
Country PL Poland
Listing WAR SCP

About Scope Fluidics S.A.

https://scopefluidics.com/

Scope Fluidics S.A. is a biotechnology company that develops innovative medical diagnostic solutions based on microfluidic technologies. The company's business model involves incubating projects within special-purpose vehicles (SPVs) with the goal of selling them to global strategic partners. Its primary project, developed by its subsidiary Bacteromic Sp. z o.o., is the BACTEROMIC system. This automated system provides rapid, comprehensive antimicrobial susceptibility testing (AST) to address the challenge of antibiotic resistance. Previously, the company developed the PCR|ONE system for rapid molecular diagnostics through its Curiosity Diagnostics SPV, which was acquired by Bio-Rad in 2022. The company focuses on creating fast, effective, and accessible diagnostic tools to improve healthcare outcomes.

Recent filings

Filing Released Lang Actions
Zakończenie procesu przyspieszonej budowy książki popytu („Proces ABB”) i ustalenie ceny emisyjnej - Content (PL)
Capital/Financing Update Classification · 1% confidence The document text, written in Polish, discusses the completion of an accelerated book-building process ('Proces ABB') aimed at offering a specific number of new common shares ('Nowe Akcje 2') via a private placement. It details the issue price (160 PLN), the number of shares subscribed (127,915), and the resulting increase in share capital. This content directly relates to fundraising, capital structure changes, and the issuance of new shares. This aligns perfectly with the definition for 'Capital/Financing Update' (CAP) or potentially 'Share Issue/Capital Change' (SHA). Since the core focus is the successful completion of a financing/placement process resulting in new shares, 'CAP' (Capital/Financing Update) is the most appropriate primary classification, as it covers the fundraising activity itself. SHA is also relevant but CAP captures the 'financing activity' aspect more broadly.
2020-10-29 Polish
Podpisanie listu intencyjnego dotyczącego przygotowania sieci dystrybucji systemu PCR|ONE na terenie kraju w celu zwiększenia atrakcyjności biznesowej systemu dla potencjalnego inwestora - Content ...
M&A Activity Classification · 1% confidence The document text is a formal announcement in Polish regarding a Letter of Intent (List intencyjny) signed between a subsidiary (Curiosity Diagnostics) and a distributor (PZ Cormay) concerning the distribution and commercialization of a product (PCR|ONE system). The text details the scope of the potential future cooperation, which includes sales, marketing, service, and customer acquisition. Crucially, the document explicitly states that the Letter of Intent expresses the preliminary intention of the parties and does not constitute a basis for a claim for concluding an agreement, nor does it have legal effects. This type of announcement, detailing a significant step towards a potential transaction (like building a distribution network to support a future sale of the subsidiary), falls under corporate actions related to mergers, acquisitions, or strategic partnerships. Given the options, 'M&A Activity' (TAR) is the most appropriate category as the stated goal is to build value for potential buyers of the subsidiary. It is not a standard financial report (10-K, IR, ER) or a management discussion (MDA), but a specific strategic development announcement.
2020-10-28 Polish
Zawarcie umowy o plasowanie akcji oraz rozpoczęcie procesu ABB - Content (PL)
Share Issue/Capital Change Classification · 1% confidence The document text discusses the execution of a placement agreement ('Umowa') for a private offering of new shares ('Nowe Akcje 2') via an accelerated book-building process ('Proces ABB'). It details the exclusion from prospectus requirements under EU Regulation 2017/1129 and specifies the types of eligible investors (qualified investors, etc.). This activity directly relates to fundraising, financing activities, and changes in the capital structure (issuance of new shares). Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). It is not a general regulatory filing (RNS) because it describes a specific corporate action related to capital, nor is it a standard share issue announcement (SHA) which usually covers splits or rights issues without detailing the placement mechanism as extensively.
2020-10-22 Polish
Decyzja w sprawie podwyższenia kapitału zakładowego w granicach kapitału docelowego oraz pozbawieniu prawa poboru obecnych akcjonariuszy Spółki - Content (PL)
Capital/Financing Update Classification · 1% confidence The document text explicitly discusses the Management Board's resolution ('uchwała') to increase the share capital ('podwyższenia kapitału zakładowego') through the issuance of new shares ('emisji akcji nowej emisji') via an accelerated book-building process ('Proces ABB'). This involves issuing new shares and potentially depriving existing shareholders of pre-emptive rights ('pozbawienie dotychczasowych akcjonariuszy Spółki w całości prawa poboru'). These actions directly relate to changes in the company's capital structure and fundraising activities. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a simple Dividend Notice (DIV).
2020-10-22 Polish
Wyniki zewnętrznych i wewnętrznych testów prewalidacyjnych systemu BacterOMIC - Content (PL)
Earnings Release Classification · 1% confidence The document is a formal announcement by the Management Board of Scope Fluidics S.A. regarding the results of external pre-validation tests for their BacterOMIC system conducted at a clinical institute. It references previous regulatory reports (raport bieżący nr 30/2020, 17/2018, 28/2019, 15/2020, 12/2020) detailing project milestones and changes. The content focuses on technical validation, comparison with reference methods, achievement of project goals, and confirmation of system performance (drug susceptibility testing). This type of detailed operational and technical update, often referencing internal testing and project progress, fits best under the category of a general Regulatory Filing (RNS) or potentially a Management Report (MDA) if it were a more comprehensive explanation of business trends. However, since it is a specific update on a technical/project milestone, and not a full financial report (10-K, IR) or a management discussion/analysis (MDA), the most appropriate general category for specific, non-standard regulatory updates that don't fit elsewhere is RNS. Given the document length (4449 chars) and its nature as a direct update on project execution rather than a formal, comprehensive report, RNS is the best fit as a specific regulatory announcement. FY 2020
2020-10-22 Polish
Prof. Carl Wittwer nowym członkiem Komitetu Doradczego - Content (PL)
Regulatory Filings Classification · 1% confidence The document text announces that Professor Carl Wittwer has joined the Advisory Committee of Scope Fluidics S.A. as of October 19, 2020. The text details his expertise in molecular diagnostics and his past achievements, emphasizing that his support will aid the company's development and international recognition. This content directly relates to changes in the company's advisory structure and the addition of key personnel/experts, which aligns best with the 'Board/Management Information' category, as advisory committees often fall under the broader scope of governance and management support structure announcements.
2020-10-19 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.